T A B L E O F C O N T E N T S

Main results
We found no RCTs comparing ICS and LABA combination with either placebo or usual care. We included one RCT that compared combined ICS and LABA with high-dose ICS in 40 adults with non-CF bronchiectasis without co-existent asthma. All participants received three months of high-dose budesonide dipropionate treatment (1600 micrograms). After three months, participants were randomly assigned to receive either high-dose budesonide dipropionate (1600 micrograms per day) or a combination of budesonide with formoterol (640 micrograms of budesonide and 18 micrograms of formoterol) for three months. The study was not blinded. We assessed it to be an RCT with overall high risk of bias. Data analysed in this review showed that those who received combined ICS-LABA (in stable state) had a significantly better transition dyspnoea index (mean difference (MD) 1.29, 95% confidence interval (CI) 0.40 to 2.18) and cough-free days (MD 12.30, 95% CI 2.38 to 22.2) compared with those receiving ICS after three months of treatment. No significant difference was noted between groups in quality of life , number of hospitalisations (odds ratio (OR) 0.26, 95% CI 0.02 to 2.79) or lung function (forced expiratory volume in one second (FEV 1 ) and forced vital capacity (FVC)). Investigators reported 37 adverse events in the ICS group versus 12 events in the ICS-LABA group but did not mention the number of individuals experiencing adverse events. Hence differences between groups were not included in the analyses. We assessed the overall evidence to be low quality.
Authors' conclusions
In adults with bronchiectasis without co-existent asthma, during stable state, a small single trial with a high risk of bias suggests that combined ICS-LABA may improve dyspnoea and increase cough-free days in comparison with high-dose ICS. No data are provided for or against, the use of combined ICS-LABA in adults with bronchiectasis during an acute exacerbation, or in children with bronchiectasis in a stable or acute state. The absence of high quality evidence means that decisions to use or discontinue combined ICS-LABA in people with bronchiectasis may need to take account of the presence or absence of co-existing airway hyper-responsiveness and consideration of adverse events associated with combined ICS-LABA.
P L A I N L A N G U A G E S U M M A R Y
Combined ICS-LABA for children and adults with bronchiectasis
A paucity of evidence is available to allow conclusions on whether combined inhaled corticosteroids (ICS)-long-acting beta 2 -agonists (LABA) are equivalent or superior to placebo or ICS monotherapy for the treatment of stable or exacerbation (flare-up) state bronchiectasis (Appendix 2).
Review question: Is any evidence available to show that combined ICS-LABA is superior to placebo or ICS monotherapy for the treatment of stable or exacerbation state bronchiectasis in children and adults? Study characteristics: A small, single-centre, non-blinded study that compared inhaled ICS-LABA with high-dose ICS.
Key results: A single study showed some benefit of the inhaled ICS-LABA combination over high-dose ICS in terms of indices of clinical stability such as dyspnoea (shortness of breath), cough-free days and number of exacerbations but failed to show significant improvement in lung function or microbiology. No data are available on children with bronchiectasis or adults with bronchiectasis during an exacerbation phase. Until further evidence becomes available, we recommend that use of combined ICS-LABA should be individualised according to the presence or likelihood of co-existing asthma features and risks of medications.
Quality of the evidence: This review is based on a single study, hence the quality of evidence is substantially limited.
Bottom line: The decision to use combined ICS-LABA in bronchiectasis must be made for individual patients on the basis of the presence or absence of bronchial hyperreactivity, until further randomised controlled trials are conducted to answer this important question.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Combination inhaled budesonide with formoterol (corticosteroids and long-acting beta 2 -agonists) compared with high-dose budesonide for bronchiectasis These results come from a single study with a small number of participants and require confirmation in other, larger studies. 
B A C K G R O U N D
Description of the intervention
How the intervention might work
Asthma-like symptoms and airway hyperresponsiveness may occur in people with bronchiectasis (Chang 2010). When they are present, this disorder may be associated with accelerated pulmonary decline when compared with bronchiectasis without asthma-like symptoms (Keistinen 1997; King 2005 In COPD, LABA combined with ICS (compared with ICS alone) reduces morbidity and mortality (Nannini 2013). In adults with asthma, the addition of LABA to ICS reduces the exacerbation rate and improves lung function (Ducharme 2010). Thus LABA combined with ICS may also be beneficial in children and adults with bronchiectasis.
Why it is important to do this review
As asthma-like symptoms and airway hyperresponsiveness may occur in people with bronchiectasis, asthma medications such as beta 2 -agonists and ICS as monotherapy or combined therapy are often used. Although asthma may co-exist with bronchiectasis, audible wheeze may reflect small airway obstruction related to airway oedema and secretions rather than bronchospasm. A history of use of asthma medication has been associated with both increased (King 2005) or reduced rate of decline in forced expiratory volume in one second (FEV 1 ) (Twiss 2006). As described above, LABA combined with ICS may confer additional clinical benefit over either medication alone. Thus, a systematic review of the benefits, or otherwise, of using LABA combined with ICS in people with bronchiectasis will be useful in guiding clinical practice.
O B J E C T I V E S
To assess the effects of inhaled long-acting beta 2 -agonists (LABA) combined with inhaled corticosteroids (ICS) in children and adults with bronchiectasis during (1) acute exacerbations and (2) stable state.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered only randomised controlled trials for inclusion in this review. Long-term cross-over trials are contentious for the target population, as recent data have shown that bronchiectasis in adults is generally a progressive condition. Nevertheless, to maintain consistency with the Cochrane review on ICS for bronchiectasis (Kapur 2009), we also included cross-over studies.
Types of participants
Children or adults with bronchiectasis (defined clinically or radiologically) not related to cystic fibrosis. We planned to exclude participants with other diseases in which bronchiectasis is not present, such as participants with asthma and COPD who do not have co-existent bronchiectasis.
Types of interventions
All types of combined ICS and LABA compared with a control (placebo, no treatment, ICS as monotherapy). ICS and LABA can be delivered through separate inhalers or by a combined inhaler. ii) Exacerbation frequency.
Types of outcome measures
Secondary outcomes
1. For acute exacerbations. i) Proportion of participants requiring hospitalisation and total number of hospitalised days.
ii) Mean difference in other objective indices (airway markers of inflammation, exhaled nitric oxide, etc).
iii) Mean difference in lung function indices (spirometry, other lung volumes, airway hyperresponsiveness).
iv) Proportion of participants experiencing adverse effects of the intervention (e.g. pharyngeal candidiasis, voice change).
2. For stable bronchiectasis. i) Mortality. ii) Radiology scores (high-resolution computed tomography scans or chest radiographs).
iii) Lung function. iv) Relevant airway markers of inflammation. v) Proportion experiencing adverse effects of the intervention (e.g. adrenal insufficiency, cataracts, linear growth).
Search methods for identification of studies Electronic searches
The search was performed by the Cochrane Airways Group. We identified trials from the Cochrane Airways Group Specialised Register of trials (CAGR), which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), part of The Cochrane LIbrary, as well as MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and from handsearching of respiratory journals and meeting abstracts (see Appendix 1 for further details) and records in the CAGR coded as 'bronchiectasis' using the following terms: (steroid* or corticosteroid or ICS or fluticasone or budesonide or beclomet* or flunisolide or mometasone or ciclesonide) AND (LABA or beta* or long-acting* or "long acting*" or *formoterol or salmeterol or indacaterol or olodacaterol)
We also conducted a search of ClinicalTrials.gov and the World Health Organization (WHO) trial portal using appropriate keywords. We searched all databases from their inception up to October 2013 with no restriction on language of publication or publication status.
Searching other resources
We checked the reference lists of all relevant primary studies and review articles for additional references. We contacted the primary author of the identified trial.
Data collection and analysis
Selection of studies
Both review authors independently assessed titles and abstracts of studies identified by the search to identify potentially relevant studies. For appropriate articles, we assigned each reference to a study identifier and assessed the full text against the inclusion criteria of this protocol. There was no disagreement between the review authors on selection of studies.
Data extraction and management
We extracted data onto a data collection form. We discussed and resolved discrepancies in the data. We transferred data from the data collection form into Review Manager 5.1 (RevMan Version 5.1) and managed it according to recommendations provided in the Cochrane Handbook for Systematic Review of Interventions ( Higgins 2011). We extracted information from the single identified study for the following characteristics.
1. Design (design, total duration of study and run-in, number of study centres and locations, withdrawals, date of study).
2. Participants (N, mean age, age range, gender, bronchiectasis severity, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, exclusion criteria).
3. Interventions (run-in, intervention treatment and inhaler type, control treatment and inhaler type).
4. Outcomes (primary and secondary outcomes specified and collected, time points reported).
Assessment of risk of bias in included studies
Both review authors independently assessed risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We assessed the risk of bias according to the following domains.
1. Random sequence generation. 2. Allocation concealment. 3. Blinding of participants and personnel.
4. Blinding of outcome assessment. 5. Incomplete outcome data. 6. Selective outcome reporting. 7. Other bias. We graded each bias domain as high, low or unclear for each study.
Measures of treatment effect
For dichotomous variables, we calculated individual and pooled statistics as odds ratios (ORs) with 95% confidence intervals (CIs). For continuous outcomes measured on the same metrics, we calculated individual and pooled statistics as mean differences (MDs) with 95% CIs. For continuous outcomes measured on different metrics, we planned to combine data using standardised mean differences (SMDs). For cross-over studies, we planned to include only the first arm and to calculate mean treatment differences from raw data, with variances extracted or imputed and entered as fixed-effect generic inverse variance (GIV) outcomes, to provide summary weighted differences and 95% CIs.
Unit of analysis issues
The unit of analysis was the participant. In cross-over trials, because there might be a carry-over effect from both ICS and LABA, we planned that only data from the first arm would be included in the meta-analysis when the data are combined with those from parallel studies, as was previously done (Kapur 2009).
Dealing with missing data
We planned to contact investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data when possible. We planned to conduct intention-totreat (ITT) analysis by assuming that missing values would have had poor outcomes. The single study included had analysed data using ITT analysis.
Assessment of heterogeneity
We had planned to use the I 2 statistic to measure heterogeneity among the trials in each analysis. As only one eligible study was identified, assessment of heterogeneity was not applicable. If we had identified substantial heterogeneity, we planned to explore this through prespecified subgroup analysis (see Subgroup analysis and investigation of heterogeneity). We would have considered levels of heterogeneity greater than 50% as substantial.
Assessment of reporting biases
We planned to attempt to contact study authors and ask them to provide missing outcome data in cases of suspected reporting bias. When this was not possible, and the missing data were thought to introduce serious bias, we planned to explore the impact of including such studies in the overall assessment of results by conducting a sensitivity analysis. We planned to investigate publication bias by visually inspecting a funnel plot if at least 10 trials were included in a meta-analysis for a single outcome. As the review is based on a single study, we have not done a funnel plot of studies.
Data synthesis
We analysed data using Review Manager 5 (RevMan Version 5.1), with a view toward using a fixed-effect MD (calculated as a weighted MD) for continuous data variables. For dichotomous outcome variables of each individual study, we calculated the ORs using a modified ITT analysis (i.e. failure assumed if participant drops out of study). This analysis assumes that participants not available for outcome assessment have not improved (and probably represents a conservative estimate of effect). We intended to calculate a number needed to treat (for an additional beneficial or harmful outcome) when possible for the different levels of risk as represented by control group event rates over a specified time period using the pooled OR, and its CI using an online calculator, Visual Rx (Cates 2003). We constructed a 'Summary of findings' table according to recommendations provided in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011)
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses on the primary outcomes of both exacerbation and stable states.
1. Children versus adults. 2. Type of ICS-LABA combination. 3. Type of control arm (placebo/no treatment/ICS). As only one included study was identified, subgroup analysis was not possible.
Sensitivity analysis
We planned to assess the impact of the following important factors on overall outcomes.
1. Study quality. 2. Variation in inclusion criteria. 3. Differences in medications used in the intervention and comparison groups.
4. Differences in outcome measures. 5. Analysis using random-effects model. 6. Analysis by "treatment received" and analysis by "intentionto-treat." We planned to remove from the meta-analysis studies considered to be at high or unclear risk of bias for methodological quality (as per the risk of bias table), and to examine any changes in the summary statistics. As only one study was eligible for inclusion in the review, sensitivity analysis was not undertaken.
Summary of findings table
We created a 'Summary of findings' table using the methods and recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011) and by using GRADEpro software. We included only the primary outcomes and one secondary outcome.
R E S U L T S Description of studies
Results of the search
The Airways Group search identified 51 potentially relevant titles (Figure 1 ). Two review authors (VG and AC) independently assessed the abstracts and retrieved three papers. Of these,only one study fulfilled the study eligibility criteria (Included studies), and the other two studies were excluded (Excluded studies). No paediatric studies were identified. No studies were identified that compared ICS-LABA versus placebo or usual care. 
Included studies
The single included study (Martinez-Garcia 2012) was conducted in Spain in 40 adults between 18 and 80 years of age with non-CF bronchiectasis. The study excluded patients with co-existent asthma. The study authors reported it as a double-blinded, parallel-group RCT comparing high-dose budesonide dipropionate treatment versus the combination of budesonide with formoterol. However, on writing to the primary author, we were informed that participants were aware of the different coloured turbuhalers. The trial was carried out in two stages. During the first stage, all participants received three months of high-dose budesonide dipropionate treatment (1600 micrograms). All other non-study drugs and steroids were stopped. After three months, participants were randomly assigned to receive either high-dose budesonide dipropionate (1600 micrograms per day) or a combination of budesonide with formoterol (640 micrograms of budesonide and 18 micrograms of formoterol) for three months. Bronchiectasis exacerbation was defined as subjective and persistent (24 hours) deterioration in at least three respiratory symptoms, including cough, dyspnoea, haemoptysis, increased sputum purulence or volume, chest pain (with or without fever), radiographic deterioration, systemic disturbances or changes in chest auscultation (Tsang 1998). Outcomes for this study were health-related quality of life (as measured by St George's Respiratory Questionnaire), transition dyspnoea index, cough-free days, rescue beta 2 -agonist inhalation as needed, change in lung function, microbiology data, number of exacerbations and adverse effects of the medications.
Excluded studies
We found two additional studies that were excluded, as they did not fulfil the inclusion criteria (see Characteristics of excluded studies). The first study (Mostafapour 2009) was published in Croatian. Investigators reported significant improvement in lung function parameters among 12 participants enrolled in the study, all of whom received a combination of salmeterol and fluticasone. This study was excluded because it was not an RCT. The second study, published in Chinese (Ding 2006), used SABA. Investigators reported that those receiving combined ICS-SABA had a reduced quantity of sputum and fewer hospitalised days compared with those given SABA alone or no therapy. Although this was an RCT, the study was excluded because the inclusion criteria required LABA, not SABA.
Risk of bias in included studies
Overall we assessed the sole included study (Martinez-Garcia 2012) to be at high risk of bias, as detailed in the 'Risk of bias' table and summarised in Figure 2 . 
Allocation
Participants were randomly assigned using a computer-generated programme, but the details were not provided. Drugs were dispensed by an independent pharmacist, but details of this were not provided in the paper.
Blinding
This study was described as double-blind. The two groups received drugs in a similar regimen (i.e. two puffs two times a day). We contacted the original study authors, who suggested that the two inhalers did not look similar and hence did not fulfil the criteria for adequate blinding.
Incomplete outcome data
The number of participants withdrawn because of adverse effects (two in the high-dose budesonide group and one lost to followup in the combination group) was reported, and ITT analysis was used; therefore we judged the trial to be at low risk of attrition bias.
Selective reporting
It was not suggested that selective reporting had occurred.
Other potential sources of bias
The study was sponsored by pharmaceutical companies, but the study authors reported that the company had no role in the design of the study, in collection and analysis of the data, or in preparation of the manuscript.
Effects of interventions
See: Summary of findings for the main comparison
Primary outcomes
The included study was conducted during stable state. Thus, only outcomes related to 'stable state' are described below.
Clinical indices of bronchiectasis control: quality of life and dyspnoea
Using the Spanish version of St George's Respiratory Questionnaire (SGRQ), Martinez-Garcia 2012 and colleagues in their paper reported significant improvement (5.3 point reduction in SGRQ score) among participants using combined ICS and LABA but no improvement in the ICS group (0.73 points). SGRQ score ranges from 0 to 100, with higher scores indicating more severe limitations. Data on differences between the groups were not mentioned in the paper. The standard deviation (SD) for mean change in the ICS-LABA group was calculated from the P value provided in the paper. As no numbers were provided for the ICS group (controls), we requested data from the study authors, who reported that the change in the ICS group was 0.73 points. Because the P value was not provided for the ICS group, we assumed the SD to be the same as that in LABA-ICS group. No significant differences between groups were reported (MD -4.57, 95% CI -12.38 to 3.24; Analysis 1.1, Figure 3 ) for SGRQ. For the outcome of transition dyspnoea index, those receiving combined ICS-LABA were significantly better than the ICS group (MD 1.29, 95% CI 0.40 to 2.18; Analysis 1.2, Figure 4 ). 
Cough-free days
A significant difference between groups was reported for coughfree days; those in the combined ICS-LABA group had 15.3% of days cough-free compared with 3% in the ICS group (MD 12.30, 95% CI 2.38 to 22.2; Analysis 1.3, Figure 5 ). 
Exacerbations
No significant difference in the number of participants who experienced exacerbations was reported (seven in the ICS group and four in the ICS-LABA group). No significant differences in hospitalisation were described between groups (OR 0.26, 95% CI 0.02 to 2.79; Analysis 1.4, Figure 6 ). We did not include exacerbations in a forest plot because it was not mentioned in the study whether seven and four participants, respectively, were having at least one exacerbation, or whether few participants experienced more than one exacerbation. 
Secondary outcomes
The single included study reported the results for other secondary outcomes including lung function and proportions of participants experiencing adverse effects of the intervention. Investigators did not use change in radiology scores as an outcome, and no deaths were reported in the trial period. Relevant inflammatory markers for the airway were not tested.
Lung function
No significant change in lung function indices was reported in the sole included study. Although FEV 1 seemed to improve more in the high-dose budesonide group (MD -14.00, 95% CI -86.83 to 58.83; Analysis 1.5, Figure 7 ) and forced vital capacity (FVC) improved more in the combination group (MD 14.00, 95% CI -63.17 to 91.17; Analysis 1.6), the differences were not significant . 
Adverse events
Study authors reported a significant difference in the number of adverse events, with the ICS group experiencing more events. They described 37 adverse events in the ICS group versus 12 events in the ICS-LABA group but did not mention the number of individuals who experienced adverse events.
D I S C U S S I O N
This review included data from only one study, and the results of the review are different from those reported in the study, as the study authors had described the study as double-blinded when it was not, and the difference in QOL between the two groups was not significant, as was stated in the study. We found that the LABA-ICS group had significantly better control of bronchiectasis in terms of cough-free days and transitional dyspnoea index, but no significant difference between groups could be found for QOL (as measured by SGRQ), lung function, number of participants with one or more exacerbations or adverse events. Given the high risk of bias and the small number of participants in the single included study, widespread applicability of these results is substantially limited.
This review summarises the best evidence available up to September 2013 and emphasises the paucity of trials testing the combination of LABA with ICS for bronchiectasis in adults and children.
Summary of main results
This review is limited to a single study eligible for inclusion (Martinez-Garcia 2012) . The combination of LABA-ICS was marginally better than high-dose ICS in improving only a few clinical indices of bronchiectasis symptom control in adults with stable state non-CF bronchiectasis without co-existent asthma. Although the study has been reported as a double-blinded trial, we assessed it as having high risk of blinding and performance bias, as well as detection bias, as the two inhalers were of different colours therefore quality of evidence across the outcomes from the study were downgraded to low quality evidence. There were no studies in support or otherwise for the ICS-LABA combination for non-CF bronchiectasis in children or adults with acute exacerbations. Overall the quality of evidence based on this review is low, and conclusions are likely to change as more evidence becomes available.
Overall completeness and applicability of evidence
Although this review provides some evidence of possible benefit derived from using combined LABA-ICS rather than high-dose inhaled steroids in patients with non-CF bronchiectasis, the results from a single study on clinical efficacy and safety of budesonideformoterol over three months cannot be applied to all LABA and ICS combinations. This review highlights the fact that there remains a paucity of high-quality data to support the routine use of combined ICS-LABA. We need more robust evidence for the use of combination LABA-ICS in stable and exacerbation states of non-CF bronchiectasis. The reason why we cannot make any significant recommendations based on the results of this review are manifold: First, this review is based on a single study in adults, and no studies in children have been identified. Second, no studies were identified for use of the LABA-ICS combination for acute exacerbations. Third, the number of participants (20 in each group) and the duration of follow-up (three months) were small. Fourth, the sole included study has a high risk of bias. Last, even though the study authors excluded participants with asthma and COPD, participants were not tested for airway hyperreactivity, and this could be a reason for the non-significant difference between the two groups. With no paediatric trial available at the time of this review, extrapolation of results to children cannot be recommended. As this was a single-study review, it was not possible to examine whether the duration of the intervention affected the findings.
Quality of the evidence
Only a single study was included in this review, hence the quality of evidence is substantially limited.
Potential biases in the review process
The Cochrane Airways Group conducted an extensive search for RCTs in children and adults with bronchiectasis. Two review authors independently screened the searches and identified one study for inclusion. We identified the sole included study itself as having overall high risk of bias. We contacted the original investigators, who kindly provided additional information about randomisation and blinding.
Agreements and disagreements with other studies or reviews
Evidence shows that a proportion of patients with bronchiectasis have increased airway hyperreactivity (Müsellim 2013; Pang 1989) , and in adults with bronchiectasis, bronchodilator use is associated with greater decline in lung function over two-year followup (King 2005) . Further, the ICS-LABA combination has proved better than ICS alone in asthma and COPD (Chroinin 2009; Nannini 2013). These results have been extrapolated to adults and children with bronchiectasis for use of a combination of ICS with LABA, but evidence to support it is lacking.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Results of a small single trial at high risk of bias suggest that LABA combined with ICS (compared with high-dose ICS) may be beneficial in adult patients with stable bronchiectasis without co-existent asthma in improving symptom control. However, in the absence of sufficient evidence, combined ICS-LABA cannot be routinely recommended for adults or children with bronchiectasis. Until further evidence becomes available, we recommend that therapy be individualised on the basis of the presence or absence of co-existing airway hyperresponsiveness and consideration of adverse events associated with combined ICS-LABA.
Implications for research
This review highlights the fact that we need large RCTs comparing the combination of inhaled LABA with ICS versus placebo or ICS in adults and children in stable and exacerbation states of bronchiectasis. Future RCTs should consider the following features.
• Double-blind, randomised, parallel studies.
• Inclusion of placebo and inhaled steroids alone.
• In the case of different coloured inhalers, a double-dummy trial.
• Minimal intervention period of six to 12 months to account for the long-term adverse effects of steroids.
• Clearly defined outcome measures, including validated QOL indices and changes in lung function, sputum volume, microbiology data and sputum and/or blood inflammatory markers.
• A priori definition of bronchial hyperreactivity with a planned subgroup analysis in participants with hyperreactivity.
• Powered to enable treatment stratification (co-existent asthma vs overall effect).
• Complete reporting of continuous (N, mean change and mean standard deviation of change) and dichotomous (denominators and event rate) data.
• Protocol-defined exacerbations and adverse events and data presented as numbers of participants as well as numbers of events.
• Well-defined adverse events, including pharyngeal candidiasis, voice change, adrenal suppression, osteopenia, effect on linear growth etc.
• Stratification based on causes of bronchiectasis and the presence or absence of Pseudomonas aeruginosa.
• Use of ITT analysis.
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